Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Xencor Inc
(NQ:
XNCR
)
17.67
+1.00 (+6.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Xencor Inc
< Previous
1
2
3
Next >
Xencor: Q4 Earnings Insights
February 23, 2022
Xencor (NASDAQ:XNCR) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
Xencor: Q3 Earnings Insights
November 08, 2021
Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their...
Via
Benzinga
Xencor's Earnings: A Preview
May 04, 2021
On Wednesday, May 05, Xencor (NASDAQ:XNCR) will release its latest earnings report. Check out Benzinga's preview to understand the implications. What Are Earnings, Net Income,...
Via
Benzinga
Earnings Scheduled For February 23, 2022
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
November 27, 2021
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to...
Via
Talk Markets
Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine
November 24, 2021
Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's...
Via
Benzinga
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma
November 22, 2021
Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a...
Via
Benzinga
Novartis Dumps Another Bispecific Candidate From Xencor Deal
November 09, 2021
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The...
Via
Benzinga
Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript
November 08, 2021
XNCR earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Earnings Scheduled For November 8, 2021
November 08, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...
Via
Benzinga
Preview: Xencor's Earnings
November 05, 2021
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody
October 04, 2021
Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global...
Via
Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Return on Capital Employed Insights for Xencor
August 20, 2021
After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
August 20, 2021
On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-...
Via
Benzinga
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
August 17, 2021
Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater...
Via
Benzinga
Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript
August 04, 2021
XNCR earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies
May 25, 2021
Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access...
Via
Benzinga
Exposures
COVID-19
Xencor Inc (XNCR) Q1 2021 Earnings Call Transcript
May 06, 2021
XNCR earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
August 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Earnings Scheduled For August 4, 2021
August 04, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
April 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...
Via
Benzinga
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
April 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.